Covid-19: Vaccine Debate
Full Debate: Read Full DebateBaroness Jolly
Main Page: Baroness Jolly (Liberal Democrat - Life peer)Department Debates - View all Baroness Jolly's debates with the Department of Health and Social Care
(4 years ago)
Lords ChamberTo ask Her Majesty's Government, following the recent analysis of the effectiveness of the Pfizer and BioNTech Covid-19 vaccine, what arrangements they have put in place to distribute approved Covid-19 vaccines (1) in the United Kingdom, and (2) internationally; and who determines the protocol for priority of access to any such vaccines.
My Lords, the NHS is preparing to be ready to deploy a Covid-19 vaccine as soon as one is safe and effective. Distribution arrangements remain flexible and include the make-up of the workforce needed to rapidly deliver a vaccination programme, training requirements, consumables and supporting infrastructure. The UK continues to work through multilaterals, such as the G7 and the G20, and with the WHO to agree collaborative approaches to supporting global vaccine development and distribution.
The Government anticipate that the vaccination programme will start with the most vulnerable and those living and working in care homes. Vaccination into muscle does not need to be administered by a clinician; any of us could be trained to do it. Which organisations are the Government working with to make this happen? Can the Minister confirm that there will be no need to take out contracts with the private sector, but that the Government will use the military, local resources—such as public health, fire and ambulance services—and trained volunteers?
My Lords, the noble Baroness is entirely right that the range of people who can administer this vaccine is extremely wide. The challenge of administering so many vaccines in such a short amount of time will indeed require the involvement of a large range of people. We are putting in the recruitment and training necessary for that to happen. I am particularly grateful to all healthcare workers, particularly those from professions such as the pharmacy industry, who are stepping forward to meet this challenge. We are not allergic, though, to using the private sector in this matter, and we will be explaining the detailed terms of our arrangements at a later date.